New eye injection enters first human safety trial for Diabetes-Related vision loss
NCT ID NCT05940428
Summary
This early-stage study is testing the safety and effects of a new drug called ASKG712, given as an injection into the eye, for people with diabetic macular edema (DME). DME is a swelling in the back of the eye that can cause vision loss in people with diabetes. The main goal is to see how safe the drug is and how the body processes it, while also checking for any early signs that it might help improve vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, China
Conditions
Explore the condition pages connected to this study.